Develops a botulinum toxin biosimilar candidate for therapeutic use by healthcare providers treating patients.
10-K for FY2025, filed Mar 30, 2026
Healthcare providers purchase botulinum toxin products that they administer to patients; prescribing decisions reflect clinical considerations, reimbursement, practice economics, workflow and familiarity with existing products.
10-K for FY2025, filed Mar 30, 2026The market is characterized by physician-administered, buy-and-bill dynamics, in which healthcare providers purchase and are reimbursed for…View ↗
10-Q for Q3 FY2026, filed Nov 16, 2026
$2.5MView ↗
8-K, filed Sep 30, 2026
The FDA agreed in principle with the Company’s proposed two-stage design for a comparative pharmacodynamic study using Compound Muscle…View ↗
From acquisition vehicle to drug developer
The older report describes a company formed to pursue a business combination, focused on medical technology. The latest report describes a biopharmaceutical company developing a therapeutic botulinum toxin biosimilar.
10-K for FY2022, filed Feb 22, 2023 10-K for FY2025, filed Mar 30, 2026We are a biopharmaceutical company focused on developing ABP-450 as a biosimilar to Botox® (onabotulinumtoxinA) for therapeutic…View ↗
Competes with AbbVie, Dysport, Xeomin, and Evolus
10-K for FY2025, filed Mar 30, 2026We are a clinical stage biopharmaceutical company with a limited operating history. Pharmaceutical product development is a highly…View ↗
Loading...